Test ID: ANAPR

Test Name: ANA Profile With Titer (If Positive)

Ordering Recommendation


Not recommended as a first-line screening test. However, it may be appropriate when there is a strong clinical suspicion of systemic autoimmune rheumatic disease (ANA-associated rheumatic diseases or connective tissue diseases) and a need to evaluate for specific auto antibodies, regardless of ANA screening results. Useful in cases where patients present with signs and symptoms consistent with systemic lupus erythematosus, Sjögren syndrome, systemic sclerosis, or mixed connective tissue disease, especially if ANA results are negative or unavailable.

 

Note: ANA testing will include ANA titer and fluorescence pattern; dsDNA and ENA testing will be performed regardless of ANA results.

Test Codes


  • EPIC Code: LAB3463
  • Exsera Order Code: ANAPR
  • CPT Code: 86038 (IFA), 86039 (Titer), 86255 (Cent), 86225 (dsDNA), 86235 (SM), 86235 (RNP), 86235 (SSA), 86235 (SSB)

Specimen Requirements


Specimen Type: Serum

Collection Tube: Serum separator tube (SST) or red top

Collection Instructions: Separate serum from cells ASAP or within 2 hours of collection. Then transfer available serum to a standard transport tube.

Volume Required: 1 mL with a minimum of 500 mcL  

Storage/Transport TemperatureRefrigerated/Frozen

Stability: Ambient (up to 8 Hours), refrigerated (up to 2 weeks/14days), frozen (up to 30 days) and avoid freeze/thaw cycles with no more than 3 in total

Unacceptable Conditions: Contaminated, heat-inactivated, containing clots fibrin or gross red blood cells, or severely lipemic hemolyzed or icteric samples

Individual Test Components


Test Code


LAB4570

LAB5254

LAB4559

LAB4803

LAB344

LAB345

Test Name


Method


Indirect Immunofluorescence assay

Fluoroenzyme Immunassay

ELISA or EIA

ELISA or EIA

ELISA or EIA

ELISA or EIA


Reference Interval


Normal Human: <1:80

Test Classification


This test has been cleared by the US Food and Drug Administration and is used per manufacturer's instructions and per Exsera's SOPs. Performance characteristics were verified by Exsera in a manner consistent with CAP/CLIA requirements.

Methodology


Indirect Immunofluorescence assay

Patient Reporting


5 Business Days

Days Performed: M-F

Aliases


ANAPR, ANA Profile with Titer

Additional Notes


ANA Profile with Titer (only titer if positive) includes: dsDNA, SM, RNP, SSA & SSB regardless of IFA result